sermorelin protocol: Frequently asked questions

Verify storage and reconstitution first. Temperature excursions or contamination during mixing are the most common causes of non-response. If storage was correct, baseline IGF-1 testing clarifies whether the pituitary is responding. Women with IGF-1 levels that remain unchanged after 4 weeks of nightly dosing may have pituitary hyporesponsiveness due to chronic stress, inadequate sleep, or underlying thyroid dysfunction. All of which blunt GH secretion regardless of GHRH stimulation. Consider extending the trial to 8 weeks before concluding the protocol is ineffective, as body composition changes lag behind IGF-1 elevation.

Reduce your next injection to 100mcg and measure fasting insulin and HbA1c. Non-response after 4 weeks typically reflects insulin resistance blunting GH receptor signaling. If fasting insulin is above 10 μIU/mL, sermorelin will elevate circulating GH but downstream tissues won't respond proportionally. Address glycemic control first with time-restricted eating or metformin, then re-escalate sermorelin after 4-6 weeks.

Never double-dose sermorelin. Resume at your standard dose on your next scheduled night. Missing 2-3 doses doesn't reset the protocol. Pulsatile GH secretion returns to baseline gradually over 7-10 days, so resuming standard dosing restores the pattern without needing a catch-up dose. Front-loading creates supraphysiologic GH spikes that increase side effect risk without benefit.

Discard it immediately and do not inject. Cloudiness indicates either microbial contamination (if bacteriostatic water was improperly stored) or peptide aggregation (if the lyophilized powder was exposed to heat before reconstitution). Properly reconstituted sermorelin is crystal-clear with no particulates. Any deviation from this signals the peptide is degraded or contaminated.

Missing doses disrupts the cumulative IGF-1 elevation required for metabolic adaptation, but it doesn't reset progress to zero. Resume nightly dosing immediately without doubling up or compensating for missed doses. The protocol timeline may extend by 1–2 weeks per week of missed doses. Symptom improvements that would have appeared at week 8 may now appear at week 10. Consistency matters more than perfection, but frequent interruptions (missing more than 7 doses within a 30-day period) compromise the protocol's effectiveness enough to warrant restarting the timeline.

Increase to 300mcg nightly for four weeks, then retest IGF-1. If levels remain below 120 ng/mL despite proper dosing, reconstitution, and storage, the issue is likely upstream. Either pituitary hyporesponsiveness or hepatic IGF-1 synthesis impairment unrelated to receptor sensitivity. At that point, alternative growth hormone secretagogues like ipamorelin or CJC-1295 (which work through different receptor pathways) may produce better results. Continuing sermorelin above 300mcg in non-responders does not improve outcomes and increases adverse event risk.

Yes. Estrogen replacement addresses vasomotor symptoms and bone density preservation but does not restore growth hormone pulsatility or reverse the metabolic shifts driven by GH decline. Women on stable estrogen therapy who add sermorelin typically see improvements in visceral fat distribution, sleep architecture, and muscle retention that estrogen alone doesn't provide. The two hormones operate through distinct pathways. Estrogen modulates estrogen receptors in reproductive tissues, bone, and brain; GH acts through IGF-1 on metabolic tissues, skeletal muscle, and adipose. Combining them addresses perimenopause symptom burden more comprehensively than either alone.

Reduce dose to 150mcg nightly and retest in four weeks. IGF-1 levels above 250 ng/mL in postmenopausal women are associated with increased breast tissue density and potential proliferative signaling without meaningful additional benefit to body composition or metabolic markers. The goal is restoration to mid-normal physiological range. Not supraphysiological levels. If 150mcg produces IGF-1 above 220 ng/mL, reduce frequency to four nights weekly rather than lowering dose further.

Transient vasomotor symptom worsening during the first 1–3 weeks is reported in approximately 15–20% of women starting GHRH analogs, likely due to autonomic recalibration as GH pulsatility increases. This is self-limiting in most cases and resolves by week 3–4. If hot flashes remain severe or increase in frequency beyond week 4, sermorelin is likely insufficient as monotherapy for vasomotor symptoms. Estrogen therapy remains first-line treatment. Sermorelin addresses metabolic and sleep disruptions effectively but does not replace estrogen's direct thermoregulatory effects.

Reduce dose by 50mcg and assess symptom resolution over two weeks. Fluid retention and joint discomfort are dose-dependent side effects caused by IGF-1's effects on sodium retention and connective tissue hydration. These symptoms typically resolve within 7–10 days of dose reduction. If symptoms persist despite lowering the dose to 150mcg, discontinue sermorelin and consult the prescribing physician. Persistent fluid retention may indicate underlying renal or cardiac issues unrelated to peptide use.

Drop your dose by 100-200mcg immediately and hold at the lower dose for 2 weeks. Water retention and joint stiffness are mediated by acute IGF-1-driven sodium retention and connective tissue edema. They resolve within 5-7 days at a reduced dose. After 2 weeks, re-escalate by 50mcg increments every 10 days instead of 100mcg jumps.

You will likely see an initial GH surge from sermorelin (measurable as elevated IGF-1 within 10–14 days) but blunt epithalon's telomerase activation through chronic IGF-1-driven somatostatin feedback. The pituitary interprets sustained high IGF-1 as a signal to reduce GH output, which means sermorelin becomes progressively less effective after week 3–4. Epithalon's genomic mechanism requires low baseline somatostatin tone to access chromatin efficiently. High IGF-1 opposes this. Start sermorelin first, establish baseline GH response, then introduce epithalon in cycles.

Sermorelin has no rebound suppression. Missing doses simply returns GH secretion to baseline until you resume. If you miss 5–7 consecutive doses, IGF-1 will decline back toward pre-treatment levels within 10–14 days, but restarting sermorelin will restore the GH pulse within 48–72 hours. This is mechanistically different from stopping exogenous rhGH, which suppresses endogenous pituitary function and requires weeks of recovery. Epithalon cycles are less forgiving: interrupting a 10-day epithalon cycle at day 6 means the telomerase activation window closes before genomic changes consolidate. Restart the full 10-day cycle rather than completing the remaining four doses.

Verify storage conditions first: sermorelin degrades rapidly if stored above 8°C or reconstituted with non-bacteriostatic water. If storage is confirmed correct, the issue is likely somatotroph GH store depletion from excessive dosing frequency. Reduce administration to every other night for 7–10 days to allow pituitary GH replenishment, then resume nightly dosing at a slightly lower dose (0.15–0.2 mg instead of 0.3 mg). Unlike synthetic GH, sermorelin cannot produce supraphysiological pulses if the pituitary's endogenous stores are depleted. This is a feature, not a flaw.

Non-response to sermorelin at 200–300mcg nightly suggests one of three conditions: advanced pituitary somatotroph exhaustion (common in individuals over 65), chronically elevated somatostatin tone (driven by metabolic syndrome, chronic stress, or exogenous glucocorticoid use), or incorrect injection timing. Verify you are injecting 30 minutes before sleep on an empty stomach. Food intake within two hours of injection blunts GH release. If timing is correct and IGF-1 remains below 150 ng/mL after four weeks, increase sermorelin to 400–500mcg or consider adding a GHRP (growth hormone-releasing peptide) like GHRP-2 or ipamorelin to bypass somatostatin inhibition.

Check baseline LH and ensure the measurement was taken during a trough (not within 90 minutes of kisspeptin dosing, when levels are artificially elevated). Non-response to kisspeptin suggests either GPR54 receptor polymorphism (rare but documented in genetic hypogonadism cases) or pituitary LH depletion from prior exogenous testosterone or GnRH agonist exposure. If baseline LH is undetectable and kisspeptin produces no response, further investigation into pituitary function (MRI, full anterior pituitary panel) is warranted before continuing the protocol.

Reduce the dose by 50% at the next administration and titrate upward more slowly over 2–3 weeks. Flushing and mild headache are documented vasodilatory effects in approximately 15–20% of research participants receiving kisspeptin at doses above 0.5 nmol/kg. The response is transient (resolves within 30–60 minutes) and not associated with serious adverse events in published trials. If symptoms persist or worsen, discontinue and consult the supervising researcher or prescriber, as this may indicate an idiosyncratic reaction rather than a dose-dependent effect.

Administer sermorelin at bedtime to align with natural nocturnal GH secretion, and dose kisspeptin in the morning or early afternoon to avoid overlap. While no pharmacokinetic interaction exists between the two peptides, their effects are temporally discrete: sermorelin produces a single GH pulse within 45–90 minutes, while kisspeptin's LH elevation peaks at 60–90 minutes but lasts up to 3 hours. Staggered timing allows clearer monitoring of each peptide's independent effect and reduces the chance of misattributing side effects or benefits to the wrong compound.

If the vial was at room temperature (20–25°C) for fewer than 8 hours, refrigerate it immediately and continue use. Partial potency loss may occur but the peptide isn't completely inactive. Beyond 8 hours or if temperature exceeded 30°C, discard the vial. Sermorelin stored above 8°C for extended periods undergoes irreversible aggregation that reduces receptor binding affinity by 70–90%. Visual inspection cannot confirm potency. Degraded peptide looks identical to viable peptide. The financial loss of one vial is preferable to continuing a protocol with inactive compound.

Verify storage and reconstitution protocol first. Temperature excursions or improper mixing are the most common causes of non-response. If storage was correct, confirm injection timing relative to meals and sleep. Insulin interference from carbohydrate intake within 2 hours of injection blunts GH release significantly. If both factors are controlled and IGF-1 remains unchanged, pituitary GH reserve depletion or growth hormone receptor defects are possible. These patients require evaluation for GH replacement therapy rather than higher sermorelin doses, which won't overcome primary GH deficiency.